Curis (CRIS) Q3 2026 earnings review
Curis advances its leukemia trial, but its cash runs low
Curis enrolled more patients into its blood cancer trials while its cash reserves ran low. The cancer drug developer cut third-quarter operating spending by 13% to $8.7 million through staff reductions, but ended September with $5 million in cash and $15.5 million in unpaid bills and accrued liabilities. Even after raising $7.5 million in an October private placement, chief executive James Dentzer's group only has enough money to fund operations into the first quarter of 2027.
| Cash and cash equivalents | $5.0M plus $7.5M raised in October 2026 |
|---|---|
| Cash funding outlook | Cut to Q1 2027 prior plan: into second half of 2027 |
| Quarterly operating expenses | $8.7M -13% from a year ago |
| TakeAim CLL study enrollment | 12 patients initial data on track for December 2026 |
⚖️ Verdict: 🔴 Bearish
The story got worse because the company's funding timeline shortened by roughly six months despite two new stock offerings in August and October. Earlier this year, management planned for cash to last into the second half of 2027 once its fifth leukemia patient was dosed and triggered warrant exercises, yet enrolling 12 patients did not bring in that money. On the positive side, the leukemia trial is on track for its December 2026 readout, and the brain lymphoma study held a 33% response rate in evaluable previously treated patients.
The question now is whether December's leukemia readout is strong enough to bring in new funding before cash runs out in early 2027. Clear drops in leftover cancer cells would let the biotech firm raise capital to finish its brain lymphoma study, while weak results would leave it short of cash with few financing options. The December 2026 clinical data release will decide the outcome.
🐂 Bull Case
Leukemia Trial Enrolls 12 Patients Ahead of Readout
Curis is developing emavusertib, an oral cancer pill designed to block two disease-driving protein pathways. In the TakeAim CLL study, the biotech company combines its pill with zanubrutinib, an approved drug for chronic lymphocytic leukemia (CLL), a blood cancer. Chief executive James Dentzer said the combination has the "potential to change the treatment landscape when combined with approved BTK inhibitors" by helping patients who only got a partial benefit from standard treatment reach a deeper remission.
Earlier this year, the drug developer aimed to dose five patients by mid-summer. By November, the study had enrolled 12 patients who had taken zanubrutinib for at least a year but still had measurable residual disease, meaning leftover cancer cells detected by a sensitive genetic test. That progress keeps initial clinical data on schedule for December 2026.
What to watch: the December 2026 clinical readout for those initial leukemia patients. A drop in leftover cancer cells toward undetectable levels would show the two-drug combination deepens responses beyond what zanubrutinib achieves alone.
Brain Lymphoma Trial Expands and Holds Response Rates
The TakeAim Lymphoma trial tests emavusertib alongside ibrutinib, an older BTK inhibitor pill, in patients with relapsed or refractory primary central nervous system lymphoma (PCNSL), a rare brain and spinal cord cancer. US and European regulators previously advised Curis that this single-arm study could support applications for accelerated approval. In July 2026, the group reported updated clinical results across 46 total patients, expanding from 24 evaluable patients in late 2025.
- Patients new to BTK inhibitors (evaluable): 100% objective response rate (5 of 5 patients), or 86% across all 7 patients
- Patients who progressed on prior BTK inhibitors (evaluable): 33% objective response rate (10 of 30 patients), compared with 37% (7 of 19) in late 2025
- All patients who progressed on prior BTK inhibitors: 26% objective response rate (10 of 39 patients)
The 33% response rate in previously treated evaluable patients matters because individuals who fail a BTK inhibitor usually go straight to hospice or supportive care. Reversing disease progression in a third of evaluable patients supports the biological case that blocking two pathways works after standard treatment fails.
What to watch: the next enrollment and clinical update for the brain lymphoma study, previously targeted for the first half of 2027. Completing full enrollment with response rates holding near one-third would allow the firm to prepare regulatory filings.
Staff Cuts Lower Research and Overhead Spending 13%
With no commercial products left after selling its Erivedge royalty rights in late 2025, Curis controls its cash drain by trimming payroll. Total operating expenses dropped 13.4% from a year ago to $8.7 million in the third quarter. Research and development spending fell 13.0% to $5.6 million, while general and administrative overhead declined 13.7% to $3.2 million.
The biotechnology firm said lower employee-related costs drove the savings in both departments, offsetting higher clinical trial bills and legal fees. Even so, the operating loss widened by 26.3% from a year ago because the prior-year quarter still included $3.2 million of royalty revenue.
What to watch: quarterly operating expenses in the fourth quarter of 2026. Keeping total quarterly spending below $9 million is necessary to prevent the cash timeline from shrinking even further.
🐻 Bear Case
Cash Timeline Shrinks From Late 2027 to Early 2027
"We are encouraged by our progress in both the TakeAim CLL study and the TakeAim Lymphoma study," chief executive James Dentzer said. Yet the money to finish those trials is running out much faster than the company projected six months ago. In the first quarter, management told investors its $15.0 million in cash, paired with up to $20.2 million from milestone-linked Series B warrants, would fund operations into the second half of 2027.
Those Series B warrants were supposed to bring in cash once Curis announced dosing its fifth leukemia patient. The trial has now enrolled 12 patients, but cash and cash equivalents still dropped to $5.0 million by September 30. Even after completing a public offering in August and raising $7.5 million net in an October private placement, Curis said the combined $12.5 million by our math will only "enable it to fund our existing operations into the first quarter of 2027."
That timeline leaves only a few months of breathing room and cuts off before the brain lymphoma trial finishes enrollment. The release makes no mention of receiving the $20.2 million from the Series B warrants, meaning the biotech group had to rely on fresh equity sales just to get past year-end.
What to watch: new financing announcements or partnership deals immediately following the December 2026 leukemia data readout. Without an immediate cash injection in December or January, the drug developer will face a liquidity crunch in the first quarter of 2027.
Frequent Share Sales Multiply Share Count Fivefold
Because Curis sold its only revenue source in late 2025, existing shareholders are paying for the clinical trials through rapid equity dilution. Weighted average common shares rose 432.9% from a year ago, climbing from a split-adjusted 784,109 shares in the third quarter of 2025 to 4,178,648 shares this quarter. By our math from prior reports, the company also executed a 1-for-20 reverse stock split during 2026 to shrink its share count.
That reverse split explains why net loss per share dropped from $9.86 a year ago to $1.94 this quarter even though the total net loss grew 5.1% to $8.1 million. The September 30 share count of 4.1 million does not yet include the shares issued in the October 2026 private placement for $7.5 million in net proceeds.
What to watch: the total share count and warrant terms in the third-quarter 10-Q filing and fourth-quarter report. Because cash only lasts into early 2027, another round of stock offerings will dilute current owners again within months.
Unpaid Bills Climb While Acute Leukemia Stays Parked
Behind the dwindling cash balance, short-term IOUs on the balance sheet are piling up. Accounts payable and accrued liabilities rose 20.3% from the end of 2025 to reach $15.5 million on September 30, 2026. That means unpaid vendor bills and accrued clinical expenses are three times as large as the $5.0 million of cash on hand at quarter-end, and still exceed the $12.5 million pro forma cash total after the October raise by our math.
The cash squeeze also keeps a major piece of the drug pipeline on the shelf. Curis noted that its studies in acute myeloid leukemia (AML), an aggressive blood and bone marrow cancer, are substantially complete, and "with additional funding the Company plans to continue development of emavusertib in AML."
What to watch: accounts payable and accrued liabilities on the fourth-quarter balance sheet. If payables keep rising while cash falls, a large share of any future fundraising will go toward paying past bills rather than running new trials.
💲 Other KPIs
Curis recorded zero revenue for a third straight quarter, down from $3.2 million a year ago. The drop happened "due to the sale of Erivedge® royalties to Oberland in the fourth quarter of 2025." Without royalty checks, every dollar of trial spending flows straight into the operating loss.
Non-operating items swung to $0.6 million of income this quarter, compared with $0.8 million of expense a year ago. For the first nine months of 2026, however, non-operating expense reached $10.7 million because the accounting value of warrant liabilities from the January 2026 private placement shifted.
Stockholders' equity — the net accounting value of assets minus liabilities — fell 53.3% from $5.5 million at the end of 2025 to $2.6 million on September 30. Nine-month net losses of $40.9 million eroded the equity cushion faster than the August stock offering replenished it.
🔮 Guidance
Cut. The cancer drug developer now expects its $5.0 million in September cash plus $7.5 million from the October private placement to fund operations into the first quarter of 2027. In the first quarter of 2026, management had planned for funding to last into the second half of 2027 assuming Series B warrants were exercised.
Unchanged. The biotech firm still plans to release initial clinical data from its Phase 2 leukemia combination study in December 2026. With 12 patients now enrolled against the initial five-patient summer target, the trial has the patient count needed for its year-end readout.
❓ Key Questions
What happened to the $20.2 million Series B warrants?
In the first quarter, management said dosing the fifth leukemia patient would trigger up to $20.2 million in Series B warrant exercises and fund the business into late 2027. With 12 patients now enrolled, why were those warrants not exercised?
How many shares were issued in the October placement?
Curis raised $7.5 million in net proceeds through a private placement in October 2026 after ending September with 4.1 million shares. Investors need to know the exact share and warrant count issued in October to measure total dilution.
When will the brain lymphoma study finish enrolling?
The company repeated its July 2026 data for 46 brain lymphoma patients rather than giving a fresh autumn patient count. How many more patients are required to complete the registrational cohort, and is the first-half 2027 readout still achievable?
How will Curis pay down $15.5 million in payables?
Accounts payable and accrued liabilities climbed to $15.5 million at quarter-end, topping the $12.5 million in combined September cash and October financing proceeds by our math. How much of those liabilities must be paid in cash over the next two quarters?